论文部分内容阅读
目的:探讨微小RNA(microRNA,miR)-125b及其靶基因信号素分子(SEMA)4C在乳腺癌组织(BRCR)及其癌旁正常组织(NCT)中的表达情况,并分析其与临床病理学特征的关联性及意义。方法:采用荧光定量PCR检测24例BRCR及其NCT中miR-125b的表达,采用免疫组织化学方法检测40例BRCR及其NCT中SEMA4C的表达。统计分析两者表达水平与患者的年龄、组织学分级、临床分期、淋巴结转移,雌、孕激素受体和人表皮生长因子受体-2(cerb B-2)等临床病理学特征间的关联性。结果:SEMA4C表达在BRCR中高于NCT,SEMA4C表达在淋巴结转移和cerb B-2表达间差异均有统计学意义(P<0.01和P<0.05),而在患者年龄,组织学分级,肿瘤临床分期及雌、孕激素受体表达间差异均无统计学意义(P>0.05)。miR-125b表达在BRCR中低于NCT(P<0.05),其表达在SEMA4C、淋巴结转移以及cerb B-2差异均有统计学意义(P=0.034~P=0.022)。结论:在乳腺浸润性导管癌中SEMA4C表达升高,miR-125b表达降低,两者均与cerb B-2过表达以及淋巴结转移均有一定关系,提示SEMA4C为miR-125b靶基因之一,miR-125b可能是一个新的乳腺癌标志物。
Objective: To investigate the expression of microRNA (miR) -125b and its target gene signal molecule (SEMA) 4C in breast cancer (BRCR) and its adjacent normal tissues (NCT) Relevance and Significance of Neo - Confucianism. Methods: The expression of miR-125b in 24 cases of BRCR and NCT was detected by real-time PCR. The expression of SEMA4C in 40 cases of BRCR and its NCT was detected by immunohistochemistry. The correlation between the expression levels and clinical pathological features such as age, histological grade, clinical stage, lymph node metastasis, estrogen, progesterone receptor and human cerulein B-2 was statistically analyzed. Sex. Results: The expression of SEMA4C in BRCR was higher than that in NCT. There was significant difference between the expression of SEMA4C in lymph node metastasis and the expression of cerb B-2 (P <0.01 and P <0.05), but not in age, histological grade, clinical stage There were no significant differences in the expression of estrogen and progesterone receptors (P> 0.05). The expression of miR-125b in BRCR was lower than that in NCT (P <0.05). The expression of miR-125b was significantly different in SEMA4C, lymph node metastasis and cerb B-2 (P = 0.034 ~ P = 0.022). Conclusions: The expression of SEMA4C is elevated and the expression of miR-125b is decreased in invasive ductal carcinomas of the breast. Both of them are correlated with the overexpression of cerb B-2 and lymph node metastasis, suggesting that SEMA4C is one of the miR-125b target genes and miR -125b may be a new breast cancer marker.